Micron Biomedical, Inc
Micron Biomedical is a leader in dissolvable microarray-based drug and vaccine delivery technology. It is a clinical-stage life science company committed to expanding access to vaccines and therapeutics globally through innovative, injection-free, painless, and self-administrable solutions. The company aims to improve health outcomes by reducing cold chain requirements, enhancing safety and efficacy, and increasing patient compliance. Micron partners with various public and private entities, including the CDC, Gates Foundation, UNICEF, PATH, and Georgia Research Alliance, to develop and commercialize its proprietary technology.
Industries
Nr. of Employees
small (1-50)
Micron Biomedical, Inc
311 Ferst Drive NW, Suite L1309, Atlanta, GA 30332-0390
Products
Dissolvable microarray patch platform for needle-free delivery
A dissolvable microarray patch platform that embeds vaccines or therapeutics into microneedles applied to the skin to enable pain-free intradermal delivery, self-administration, reduced cold-chain dependence and elimination of sharps waste.
Dissolvable microarray patch platform for needle-free delivery
A dissolvable microarray patch platform that embeds vaccines or therapeutics into microneedles applied to the skin to enable pain-free intradermal delivery, self-administration, reduced cold-chain dependence and elimination of sharps waste.
Services
On-site production of microarray patch clinical materials under current Good Manufacturing Practice conditions.
Development of formulations for incorporation into dissolvable microarray patches and optimization of manufacturing processes for patch production.
Design and prototyping of microarray geometry, backing materials and package formats suitable for distribution and user handling.
Development and execution of analytical assays and stability studies to support product development and regulatory submissions.
Regulatory planning and preparation of submissions to progress microarray-delivered products through clinical development.
Protocol development, site support and operational execution for preclinical and human clinical studies, including pediatric age de-escalation designs.
On-site production of microarray patch clinical materials under current Good Manufacturing Practice conditions.
Development of formulations for incorporation into dissolvable microarray patches and optimization of manufacturing processes for patch production.
Design and prototyping of microarray geometry, backing materials and package formats suitable for distribution and user handling.
Development and execution of analytical assays and stability studies to support product development and regulatory submissions.
Regulatory planning and preparation of submissions to progress microarray-delivered products through clinical development.
Protocol development, site support and operational execution for preclinical and human clinical studies, including pediatric age de-escalation designs.
Expertise Areas
- Needle-free transdermal delivery
- Formulation development for thermostability
- Clinical trial design and execution (including pediatric trials)
- cGMP manufacturing and scale-up
Key Technologies
- Dissolvable microarray (microneedle) patches
- Intradermal delivery
- Thermostable vaccine and drug formulations
- Sustained-release transdermal delivery
News & Updates
The company raised over $33 million to support the development and commercialization of its microarray technology for drug and vaccine delivery.
Micron secured a $2 million award from BARDA to develop a needle-free flu vaccine using mRNA technology in collaboration with Zipcode Bio.
CEPI and Micron Biomedical Accelerate Needle-Free Vaccines against Disease X with $3.7 Million Grant
Funding from CEPI to advance research on needle-free vaccines against Disease X, building on COVID-19 learnings.
Received grants to support the development of needle-free measles and rubella vaccines and to conduct Phase 2 trials in infants.
Awarded for scientific innovation in the field of vaccine delivery technology.
Received an award recognizing its innovation in biotech medical technology.
The company raised over $33 million to support the development and commercialization of its microarray technology for drug and vaccine delivery.
Micron secured a $2 million award from BARDA to develop a needle-free flu vaccine using mRNA technology in collaboration with Zipcode Bio.
CEPI and Micron Biomedical Accelerate Needle-Free Vaccines against Disease X with $3.7 Million Grant
Funding from CEPI to advance research on needle-free vaccines against Disease X, building on COVID-19 learnings.
Received grants to support the development of needle-free measles and rubella vaccines and to conduct Phase 2 trials in infants.
Awarded for scientific innovation in the field of vaccine delivery technology.
Received an award recognizing its innovation in biotech medical technology.